Abstract
Regarding the low penetration of biosimilars drugs in the French market, the government introduce two incentives to increase biosimilar use. First, the “general case” redirects 20% of the price difference between reference product and its biosimilar to hospitals for every biosimilar delivered in community pharmacy from these hospital’s prescriptions. Second, the “experimental case” increases the premium to 30% by specifically targeting prescribing hospital clinical units for every biosimilar delivered in community pharmacy from these clinical unit’s prescriptions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
